04 June 2022 | News
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Image Credit: Shutterstock
C2i Genomics, a cancer intelligence company based in the US, has announced a strategic partnership with Mumbai-based startup Karkinos Healthcare, to co-develop the minimal residual disease (MRD) market in India.
The partnership enables C2i Genomics to bring innovative cancer detection technology to drive R&D, future pharma partnerships and clinical use in India and supports the company’s long-term goals to scale pharma R&D projects around the globe.
The partnership will expand MRD monitoring within the Karkinos’ health system and its partners using the C2i Genomics’ ultrasensitive whole-genome analysis.
The C2inform MRD test enables physicians to trace small amounts of persistent or recurrent cancer much earlier and at far lower levels than currently available technologies. C2i Genomics’ SaaS solution utilises a cloud-based platform to perform cancer tumour burden monitoring on a global scale, utilising equipped labs and sequencing networks worldwide. By using machine learning and AI technology to analyse patients’ blood for early detection of cancer recurrence or resistance, C2i Genomics directly drives more informed treatment decisions and personaliszed treatment plans.